Smarter Signal Management: AI, big data, and predictive analytics

Author(s)Oracle

What if you could predict potential safety issues before clinical development begins? Innovative new signal detection and management approaches have been developed to help clinical trial sponsors, manufacturers, and CROs combat safety-related challenges and provide insight to be used to predict potential safety issues even before clinical development begins. Applying those learnings to their choice of initial research candidates can ultimately mean safer medicines for patients.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

November 10th, 2026

Pharmaceutical Executive Daily: FDA Requires Safety Label Update on GLP-1 Receptor Agonist

FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.

November 10th, 2026

AstraZeneca Acquires Omniose, Adding Bioconjugation Platform to Vaccine Pipeline

AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.

November 10th, 2026

FDA Requests Updated Safety Label Warning Across All GLP-1 Receptor Agonist for Potential Risk of NAION

FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.

November 10th, 2026

FDA Approves asundexian for Secondary Stroke Risk Reduction

FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention.

November 10th, 2026

Where AI Can Strengthen Clinical Research, and Where Patient Input is More Important

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.

November 10th, 2026

Adjusting for Tumor Mutations: Q&A with Dr. Brian Corgiat

Ignite Proteomics’ senior clinical research scientist discusses how flaws in testing tumors may lead to some patients not receiving the correct treatment.

November 9th, 2026

Pharmaceutical Executive Daily: argenx Acquires Unnatural Products Inc.

argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.

November 9th, 2026

Single Partner Platforms: Enhancing the Prescription Journey for Manufacturers

Single-partner platforms can unify manufacturers, prescribers, and patients to eliminate gaps, cut costs, and boost treatment adherence.

Smarter Signal Management: AI, big data, and predictive analytics

Related to this article

Trending on PharmExec

FDA Requests Updated Safety Label Warning Across All GLP-1 Receptor Agonist for Potential Risk of NAION

Where AI Can Strengthen Clinical Research, and Where Patient Input is More Important

FDA Approves asundexian for Secondary Stroke Risk Reduction

AstraZeneca Acquires Omniose, Adding Bioconjugation Platform to Vaccine Pipeline

argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities